ClinicalTrials.gg
CompletedNCT01573767Updated Jan 9, 2017Results posted

Dose-ranging Study of Vilanterol (VI) Inhalation Powder in Children

A Phase 2 interventional study of Fluticasone propionate 100mcg and Placebo in Asthma, sponsored by GlaxoSmithKline. Completed at 121 sites in 14 countries. Open to participants aged 5 Years to 11 Years. Per ClinicalTrials.gov, last updated 2017-01-09.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
463
Allocation
Randomized
Ages
5 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies testing vilanterol in Asthma — none open to participants now, 2 under way, 2 of them phase 3. vilanterol · Asthma.

Enrollment
4th of 30
463 · median 69
Started
2012
with 4 others
Phase 2
6 of 30
none open now
Registered
18th of 30
by date
Lead sponsor
27 of 30
GlaxoSmithKline

Among the 30 studies testing vilanterol in Asthma, this one is the 4th largest by enrollment, is one of 5 that started in 2012, is one of 6 in phase 2, and was the 18th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 30 studies testing vilanterol in Asthma is open now. The open studies under Asthma, anywhere →

About vilanterol

vilanterol: first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 5 Years to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 30 studies testing vilanterol in Asthma as a file.
02

Study summary

This is a Phase IIb, multi-centre, randomised, double-blind, parallel-group, placebo-controlled study in children aged 5-11 years with persistent uncontrolled asthma. Subjects entering the run-in period will stop their current asthma medication and be given open label fluticasone propionate (FP) 100mcg twice daily via DISKUS/ACCUHALER and salbutamol/albuterol as required to use throughout the run-in and double-blind treatment period. At Visit 3 subjects meeting the randomization eligibility criteria will receive vilanterol (6.25mcg, 12.5mcg, or 25mcg,) or placebo via the Novel Dry Powder Inhaler (NDPI) once daily for 4 weeks in addition to open-label fluticasone propionate twice daily throughout the treatment period. Primary endpoints consist of change from baseline in clinic visit trough (pre-bronchodilator and pre-dose) PEF at the end of the 28-day treatment period in all subjects. Safety assessments include adverse events, oropharyngeal examinations, clinical chemistry, 12-lead ECG, and vital signs. Blood samples will be taken from all subjects for pharmacokinetic analysis to determine plasma concentrations of vilanterol at specific time intervals relative to the dose of study drug.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
5 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written from at least one parent/ legal guardian to take part in the study.:
  • Diagnosis of asthma
  • pre-bronchodilator PEF between ≥50% to ≤90% of their best post-bronchodilator value
  • Receiving stable asthma therapy of short acting beta-agonist (SABA) plus ICS (total daily dose FP 200mcg or equivalent)

Exclusion criteria

Exclusion Criteria:

  • history of life-threatening asthma
  • history of asthma exacerbation for asthma within 6 months prior to screening.
  • Culture-documented or suspected bacterial or viral infection
  • significant abnormality or medical condition
  • Present use of any tobacco products
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
463 participants (actual)

Study arms

  • Active comparator
    Arm 1

    Vilanterol 25mcg inhalation powder inhaled once daily in the PM via the new powder inhaler

    Drug: Fluticasone propionate 100mcg · Drug: Vilanterol

  • Active comparator
    Arm 2

    Vilanterol 12.5mcg inhalation powder inhaled once daily in the PM via the new powder inhaler

    Drug: Fluticasone propionate 100mcg · Drug: Vilanterol

  • Active comparator
    Arm 3

    Vilanterol 6.25mcg inhalation powder inhaled once daily in the PM via the new powder inhaler

    Drug: Fluticasone propionate 100mcg · Drug: Vilanterol

  • Placebo comparator
    Arm 4

    Placebo inhalation powder inhaled once daily in the PM via the new powder inhaler

    Drug: Fluticasone propionate 100mcg · Drug: Placebo

Interventions

  • all subjects recieve open-label Flovent twice daily duirng the run in and treatment period

  • DrugPlacebo

    Placebo inhalation powder during treatment period

  • subjects will recieve 4 weeks via NDPI during treament period

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Daily Pre-dose Evening (PM) Peak Expiratory Flow (PEF) From Participant Electronic Daily Diary Averaged Over the 4-week Treatment Period

    PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. PEF was measured by the participants using a hand-held electronic peak flow meter each evening prior to the dose of study medication and any rescue albuterol/salbutamol inhalation aerosol use each morning. The best of three measurements was recorded. Change from Baseline was calculated as the value of the averaged daily PM PEF over the 4-week Treatment Period minus the Baseline value. The Baseline PEF value is defined as the average of the last 7 days of the Run-in Phase. The analysis was performed using an analysis of covariance (ANCOVA) model with covariates of Baseline, region, sex, age, and treatment. Only those participants contributing data per the daily eDiary were analyzed.

    Time frame: Baseline; Week 1 up to Week 4

Secondary outcomes

  1. Change From Baseline in Evening Clinic Visit Trough (Pre-bronchodilator and Pre-dose) Forced Expiratory Volume in One Second (FEV1) at the End of the 4-week Treatment Period in Children Who Could Perform the Maneuver

    Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 is defined as a pre-dose FEV1 measurement taken at a clinic visit while still on treatment. Change from Baseline in trough FEV1 at the end of the 4-week Treatment Period was defined using the pre-dose FEV1 measurement taken at the Week 4 clinic visit. Change from Baseline was calculated as the Week 4 trough FEV1 value minus the Baseline value. The Baseline FEV1 value is defined as the value at Visit 3 (randomization). The analysis was performed using an ANCOVA model with covariates of Baseline trough FEV1, region, sex, age, and treatment. The last observation carried forward (LOCF) method was used to impute missing data, in which the last non-missing post-Baseline on-treatment measurement at scheduled clinic visits was used to impute the missing measurements.

    Time frame: Baseline; Week 4

  2. Change From Baseline in the Percentage of Rescue-free 24-hour Periods During the 4-week Treatment Period

    The number of inhalations of rescue albuterol/salbutamol inhalation aerosol (medication used to relieve symptoms immediately) used during the day and night) was recorded by the participants in a daily diary. A 24-hour period in which a participant's responses to both the morning and evening assessments indicated no use of rescue medication was considered as rescue free. Participants who were rescue free for 24-hour periods during the 4-week Treatment Period were assessed. The Baseline value was derived from the last 7 days of the daily diary prior to the randomization of the participant. Change from Baseline is calculated as the average value during the 4-week Treatment Period minus the value at Baseline. The Baseline value is defined as the value at Visit 3 (randomization). Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.

    Time frame: Baseline; Week 1 up to Week 4

  3. Change From Baseline in Daily Morning (AM) PEF Averaged Over the 4-week Treatment Period

    PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. PEF was measured by the participants using a hand-held electronic peak flow meter each morning prior to the dose of study medication and any rescue albuterol/salbutamol inhalation aerosol use. Change from Baseline was calculated as the value of the averaged daily AM PEF over the 4-week Treatment Period (at Week 4) minus the Baseline value. The Baseline value is defined as the value at Visit 3 (randomization). The analysis was performed using an ANCOVA model with covariates of Baseline, region, sex, age, and treatment group.

    Time frame: Baseline; Week 1 up to Week 4

  4. Change From Baseline in Evening (PM) PEF Over the Last 7 Days of the Treatment Period (Week 4)

    PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. PEF was measured by the participants using a hand-held electronic peak flow meter each evening prior to the dose of study medication and any rescue albuterol/salbutamol inhalation aerosol use. Change from Baseline is calculated as the value over the last 7 days of the Treatment Period minus the Baseline value. The Baseline value is defined as the value at Visit 3 (randomization). The analysis was performed using an ANCOVA model with covariates of Baseline, region, sex, age, and treatment group. The LOCF method was used to impute missing data, in which the last non-missing post-Baseline on-treatment measurement at scheduled clinic visits was used to impute the missing measurements.

    Time frame: Baseline; Week 4

  5. Change From Baseline in AM PEF Over the Last 7 Days of the Treatment Period (Week 4)

    PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. PEF was measured by the participants using a hand-held electronic peak flow meter each morning prior to the dose of study medication and any rescue albuterol/salbutamol inhalation aerosol use. Change from Baseline is calculated as the value of the averaged daily AM PEF over the 4-week Treatment Period (at Week 4) minus the Baseline value. The Baseline value is defined as the value at Visit 3 (randomization). The analysis was performed using an ANCOVA model with covariates of Baseline, region, sex, age, and treatment group.

    Time frame: Baseline; Week 4

  6. Change From Baseline in the Percentage of Symptom-free 24-hour Periods During the 4-week Treatment Period

    Asthma symptoms were recorded in a daily eDairy by the participants every day in the morning and evening before taking any rescue or study medication and before the PEF measurement. A 24-hour (hr) period in which a participant's responses to both the morning and evening assessments indicated no symptoms was considered to be symptom free. The Baseline symptom-free value is defined as the value at Visit 3 (randomization). Change from Baseline was calculated as the averaged value during the 4-week Treatment Period minus the Baseline value. The analysis was performed using an ANCOVA model with covariates of Baseline, region, sex, age, and treatment group.

    Time frame: Baseline; Week 1 up to Week 4

07

Results

Posted Apr 3, 2015

Participant flow

1208 participants (par.) were screened; 760 entered the Run-in Phase, 463 were randomized, and 2 received study medication (SM) but weren't randomized/included in the Intent-to-Treat (ITT) Population (randomized to treatment and receiving \>=1 SM dose). 7 randomized par. didn't receive SM; hence, 456 par. comprised the ITT Population.

Participant flow — Overall Study
MilestonePlaceboVI 6.25 µg ODVI 12.5 µg ODVI 25 µg OD
Started115114113114
Completed93939990
Not completed22211424
Withdrew: Adverse event0101
Withdrew: Lack of efficacy18151217
Withdrew: Protocol violation3113
Withdrew: Lost to follow-up0111
Withdrew: Physician decision1202
Withdrew: Withdrawal by subject0100

Outcome measures

PrimaryChange From Baseline in Daily Pre-dose Evening (PM) Peak Expiratory Flow (PEF) From Participant Electronic Daily Diary Averaged Over the 4-week Treatment Period

PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. PEF was measured by the participants using a hand-held electronic peak flow meter each evening prior to the dose of study medication and any rescue albuterol/salbutamol inhalation aerosol use each morning. The best of three measurements was recorded. Change from Baseline was calculated as the value of the averaged daily PM PEF over the 4-week Treatment Period minus the Baseline value. The Baseline PEF value is defined as the average of the last 7 days of the Run-in Phase. The analysis was performed using an analysis of covariance (ANCOVA) model with covariates of Baseline, region, sex, age, and treatment. Only those participants contributing data per the daily eDiary were analyzed.

Time frame:
Baseline; Week 1 up to Week 4
Reported as:
Least squares mean · Liters per minute (L/min)
Change From Baseline in Daily Pre-dose Evening (PM) Peak Expiratory Flow (PEF) From Participant Electronic Daily Diary Averaged Over the 4-week Treatment Period
Liters per minute (L/min)PlaceboVI 6.25 µg ODVI 12.5 µg ODVI 25 µg OD
Change From Baseline in Daily Pre-dose Evening (PM) Peak Expiratory Flow (PEF) From Participant Electronic Daily Diary Averaged Over the 4-week Treatment Period215.9 ± 2.53221.4 ± 2.53222.4 ± 2.54220.3 ± 2.56
Statistical analysis
  • Placebo vs VI 25 µg OD · ANCOVA · p = 0.227 (Inference for VI 12.5 µg versus (vs) placebo was dependent upon statistical significance (SS) having first been achieved for VI 25 µg vs placebo; inference for VI 6.25 µg vs placebo was dependent on SS having been achieved for VI 12.5 µg vs placebo.) · Mean difference (final values): 4.4 · 95% CI -2.7 to 11.4
  • Placebo vs VI 12.5 µg OD · ANCOVA · p = 0.073 · Mean difference (final values): 6.4 · 95% CI -0.6 to 13.5
  • Placebo vs VI 6.25 µg OD · ANCOVA · p = 0.127 · Mean difference (final values): 5.5 · 95% CI -1.6 to 12.5
SecondaryChange From Baseline in Evening Clinic Visit Trough (Pre-bronchodilator and Pre-dose) Forced Expiratory Volume in One Second (FEV1) at the End of the 4-week Treatment Period in Children Who Could Perform the Maneuver

Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 is defined as a pre-dose FEV1 measurement taken at a clinic visit while still on treatment. Change from Baseline in trough FEV1 at the end of the 4-week Treatment Period was defined using the pre-dose FEV1 measurement taken at the Week 4 clinic visit. Change from Baseline was calculated as the Week 4 trough FEV1 value minus the Baseline value. The Baseline FEV1 value is defined as the value at Visit 3 (randomization). The analysis was performed using an ANCOVA model with covariates of Baseline trough FEV1, region, sex, age, and treatment. The last observation carried forward (LOCF) method was used to impute missing data, in which the last non-missing post-Baseline on-treatment measurement at scheduled clinic visits was used to impute the missing measurements.

Time frame:
Baseline; Week 4
Reported as:
Least squares mean · Liters
Change From Baseline in Evening Clinic Visit Trough (Pre-bronchodilator and Pre-dose) Forced Expiratory Volume in One Second (FEV1) at the End of the 4-week Treatment Period in Children Who Could Perform the Maneuver
LitersPlaceboVI 6.25 µg ODVI 12.5 µg ODVI 25 µg OD
Change From Baseline in Evening Clinic Visit Trough (Pre-bronchodilator and Pre-dose) Forced Expiratory Volume in One Second (FEV1) at the End of the 4-week Treatment Period in Children Who Could Perform the Maneuver0.223 ± 0.02870.166 ± 0.02920.240 ± 0.02850.193 ± 0.0288
Statistical analysis
  • Placebo vs VI 6.25 µg OD · Mean difference (final values): -0.057 · 95% CI -0.138 to 0.024
  • Placebo vs VI 12.5 µg OD · Mean difference (final values): 0.017 · 95% CI -0.063 to 0.096
  • Placebo vs VI 25 µg OD · Mean difference (final values): -0.030 · 95% CI -0.110 to 0.051
SecondaryChange From Baseline in the Percentage of Rescue-free 24-hour Periods During the 4-week Treatment Period

The number of inhalations of rescue albuterol/salbutamol inhalation aerosol (medication used to relieve symptoms immediately) used during the day and night) was recorded by the participants in a daily diary. A 24-hour period in which a participant's responses to both the morning and evening assessments indicated no use of rescue medication was considered as rescue free. Participants who were rescue free for 24-hour periods during the 4-week Treatment Period were assessed. The Baseline value was derived from the last 7 days of the daily diary prior to the randomization of the participant. Change from Baseline is calculated as the average value during the 4-week Treatment Period minus the value at Baseline. The Baseline value is defined as the value at Visit 3 (randomization). Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.

Time frame:
Baseline; Week 1 up to Week 4
Reported as:
Least squares mean · Percentage of rescue-free 24-hr periods
Change From Baseline in the Percentage of Rescue-free 24-hour Periods During the 4-week Treatment Period
Percentage of rescue-free 24-hr periodsPlaceboVI 6.25 µg ODVI 12.5 µg ODVI 25 µg OD
Change From Baseline in the Percentage of Rescue-free 24-hour Periods During the 4-week Treatment Period14.4 ± 2.9712.2 ± 2.9715.8 ± 2.982.98 ± 3.01
Statistical analysis
  • Placebo vs VI 6.25 µg OD · Mean difference (final values): -2.3 · 95% CI -10.5 to 6.0
  • Placebo vs VI 12.5 µg OD · Mean difference (final values): 1.3 · 95% CI -6.9 to 9.6
  • Placebo vs VI 25 µg OD · Mean difference (final values): 8.7 · 95% CI 0.4 to 17.0
SecondaryChange From Baseline in Daily Morning (AM) PEF Averaged Over the 4-week Treatment Period

PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. PEF was measured by the participants using a hand-held electronic peak flow meter each morning prior to the dose of study medication and any rescue albuterol/salbutamol inhalation aerosol use. Change from Baseline was calculated as the value of the averaged daily AM PEF over the 4-week Treatment Period (at Week 4) minus the Baseline value. The Baseline value is defined as the value at Visit 3 (randomization). The analysis was performed using an ANCOVA model with covariates of Baseline, region, sex, age, and treatment group.

Time frame:
Baseline; Week 1 up to Week 4
Reported as:
Least squares mean · L/min
Change From Baseline in Daily Morning (AM) PEF Averaged Over the 4-week Treatment Period
L/minPlaceboVI 6.25 µg ODVI 12.5 µg ODVI 25 µg OD
Change From Baseline in Daily Morning (AM) PEF Averaged Over the 4-week Treatment Period6.4 ± 2.4212.0 ± 2.4313.9 ± 2.4413.7 ± 2.46
Statistical analysis
  • Placebo vs VI 6.25 µg OD · Mean difference (final values): 5.5 · 95% CI -1.2 to 12.3
  • Placebo vs VI 12.5 µg OD · Mean difference (final values): 7.5 · 95% CI 0.7 to 14.2
  • Placebo vs VI 25 µg OD · Mean difference (final values): 7.2 · 95% CI 0.4 to 14.0
SecondaryChange From Baseline in Evening (PM) PEF Over the Last 7 Days of the Treatment Period (Week 4)

PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. PEF was measured by the participants using a hand-held electronic peak flow meter each evening prior to the dose of study medication and any rescue albuterol/salbutamol inhalation aerosol use. Change from Baseline is calculated as the value over the last 7 days of the Treatment Period minus the Baseline value. The Baseline value is defined as the value at Visit 3 (randomization). The analysis was performed using an ANCOVA model with covariates of Baseline, region, sex, age, and treatment group. The LOCF method was used to impute missing data, in which the last non-missing post-Baseline on-treatment measurement at scheduled clinic visits was used to impute the missing measurements.

Time frame:
Baseline; Week 4
Reported as:
Least squares mean · L/min
Change From Baseline in Evening (PM) PEF Over the Last 7 Days of the Treatment Period (Week 4)
L/minPlaceboVI 6.25 µg ODVI 12.5 µg ODVI 25 µg OD
Change From Baseline in Evening (PM) PEF Over the Last 7 Days of the Treatment Period (Week 4)5.9 ± 3.449.4 ± 3.4413.7 ± 3.4511.1 ± 3.48
Statistical analysis
  • Placebo vs VI 6.25 µg OD · Mean difference (final values): 3.5 · 95% CI -6.1 to 13.1
  • Placebo vs VI 12.5 µg OD · Mean difference (final values): 7.8 · 95% CI -1.8 to 17.4
  • Placebo vs VI 25 µg OD · Mean difference (final values): 5.2 · 95% CI -4.4 to 14.9
SecondaryChange From Baseline in AM PEF Over the Last 7 Days of the Treatment Period (Week 4)

PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. PEF was measured by the participants using a hand-held electronic peak flow meter each morning prior to the dose of study medication and any rescue albuterol/salbutamol inhalation aerosol use. Change from Baseline is calculated as the value of the averaged daily AM PEF over the 4-week Treatment Period (at Week 4) minus the Baseline value. The Baseline value is defined as the value at Visit 3 (randomization). The analysis was performed using an ANCOVA model with covariates of Baseline, region, sex, age, and treatment group.

Time frame:
Baseline; Week 4
Reported as:
Least squares mean · L/min
Change From Baseline in AM PEF Over the Last 7 Days of the Treatment Period (Week 4)
L/minPlaceboVI 6.25 µg ODVI 12.5 µg ODVI 25 µg OD
Change From Baseline in AM PEF Over the Last 7 Days of the Treatment Period (Week 4)7.4 ± 3.4513.3 ± 3.4717.0 ± 3.4814.4 ± 3.51
Statistical analysis
  • Placebo vs VI 6.25 µg OD · Mean difference (final values): 5.9 · 95% CI -3.7 to 15.6
  • Placebo vs VI 12.5 µg OD · Mean difference (final values): 9.7 · 95% CI 0.0 to 19.3
  • Placebo vs VI 25 µg OD · Mean difference (final values): 7.0 · 95% CI -2.7 to 16.7
SecondaryChange From Baseline in the Percentage of Symptom-free 24-hour Periods During the 4-week Treatment Period

Asthma symptoms were recorded in a daily eDairy by the participants every day in the morning and evening before taking any rescue or study medication and before the PEF measurement. A 24-hour (hr) period in which a participant's responses to both the morning and evening assessments indicated no symptoms was considered to be symptom free. The Baseline symptom-free value is defined as the value at Visit 3 (randomization). Change from Baseline was calculated as the averaged value during the 4-week Treatment Period minus the Baseline value. The analysis was performed using an ANCOVA model with covariates of Baseline, region, sex, age, and treatment group.

Time frame:
Baseline; Week 1 up to Week 4
Reported as:
Least squares mean · Percentage of symptom-free 24-hr periods
Change From Baseline in the Percentage of Symptom-free 24-hour Periods During the 4-week Treatment Period
Percentage of symptom-free 24-hr periodsPlaceboVI 6.25 µg ODVI 12.5 µg ODVI 25 µg OD
Change From Baseline in the Percentage of Symptom-free 24-hour Periods During the 4-week Treatment Period9.9 ± 2.6510.1 ± 2.6518.3 ± 2.6619.7 ± 2.69
Statistical analysis
  • Placebo vs VI 6.25 µg OD · Mean difference (final values): 0.2 · 95% CI -7.2 to 7.5
  • Placebo vs VI 12.5 µg OD · Mean difference (final values): 8.3 · 95% CI 1.0 to 15.7
  • Placebo vs VI 25 µg OD · Mean difference (final values): 9.8 · 95% CI 2.3 to 17.2

Adverse events

Collected over On-treatment serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from the start of study medication until the follow-up visit (up to 9 weeks).. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/115 (0%)10/115 (8.7%)
VI 6.25 OD—0/114 (0%)17/114 (14.9%)
VI 12.5 OD—0/113 (0%)12/113 (10.6%)
VI 25 OD—1/114 (0.9%)11/114 (9.6%)
Most frequent serious events
Most frequent serious events
EventPlaceboVI 6.25 ODVI 12.5 ODVI 25 OD
AppendicitisInfections and infestations0/1150/1140/1131/114
Most frequent other events
Most frequent other events
EventPlaceboVI 6.25 ODVI 12.5 ODVI 25 OD
NasopharyngitisInfections and infestations8/1158/11410/1139/114
HeadacheNervous system disorders4/1156/1142/1132/114
InfluenzaInfections and infestations0/1154/1140/1130/114

Baseline characteristics

Age, Continuous
Age, Continuous(Years)PlaceboVI 6.25 µg ODVI 12.5 µg ODVI 25 µg ODTotal
Mean8.0 ± 1.818.0 ± 1.957.9 ± 1.747.9 ± 1.727.9 ± 1.80
Gender
Gender(Participants)PlaceboVI 6.25 µg ODVI 12.5 µg ODVI 25 µg ODTotal
Female50434245180
Male65717169276
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboVI 6.25 µg ODVI 12.5 µg ODVI 25 µg ODTotal
African American/African Heritage555318
American Indian or Alaska Native1621171872
Asian - Japanese Heritage555520
Asian - South East Asian Heritage11215
White - Arabic/North African Heritage11013
White - White/Caucasian/European Heritage67625561245
Mixed Race2019292593
08

Study locations

121 sites
  • GSK Investigational Site
    Birmingham, Alabama 35209, United States
  • GSK Investigational Site
    Mobile, Alabama 36608, United States
  • GSK Investigational Site
    Little Rock, Arkansas 72205, United States
  • GSK Investigational Site
    Huntington Beach, California 92647, United States
  • GSK Investigational Site
    Long Beach, California 90808, United States
  • GSK Investigational Site
    Mission Viejo, California 92691, United States
  • GSK Investigational Site
    Newport Beach, California 92663, United States
  • GSK Investigational Site
    Orange, California 92868, United States
  • GSK Investigational Site
    Rolling Hills Estates, California 90274, United States
  • GSK Investigational Site
    Aventura, Florida 33180, United States
  • GSK Investigational Site
    Miami, Florida 33173, United States
  • GSK Investigational Site
    Tampa, Florida 33613, United States
  • GSK Investigational Site
    Columbus, Georgia 31904, United States
  • GSK Investigational Site
    Savannah, Georgia 31406, United States
  • GSK Investigational Site
    Normal, Illinois 61761, United States
  • GSK Investigational Site
    Shiloh, Illinois 62269, United States
  • GSK Investigational Site
    Lenexa, Kansas 66215, United States
  • GSK Investigational Site
    Nicholasville, Kentucky 40356, United States
  • GSK Investigational Site
    White Marsh, Maryland 21162, United States
  • GSK Investigational Site
    Columbia, Missouri 65203, United States
  • GSK Investigational Site
    Omaha, Nebraska 68107, United States
  • GSK Investigational Site
    Raleigh, North Carolina 27607, United States
  • GSK Investigational Site
    Cincinnati, Ohio 45231, United States
  • GSK Investigational Site
    Dayton, Ohio 45414, United States
  • GSK Investigational Site
    Oklahoma City, Oklahoma 73112, United States
  • GSK Investigational Site
    Medford, Oregon 97504, United States
  • GSK Investigational Site
    Pittsburgh, Pennsylvania 15241, United States
  • GSK Investigational Site
    Charleston, South Carolina 29406, United States
  • GSK Investigational Site
    Orangeburg, South Carolina 29118, United States
  • GSK Investigational Site
    Austin, Texas 78750, United States
  • GSK Investigational Site
    Dallas, Texas 75230, United States
  • GSK Investigational Site
    Spring, Texas 77379, United States
  • GSK Investigational Site
    Waco, Texas 76712, United States
  • GSK Investigational Site
    South Burlington, Vermont 05403, United States
  • GSK Investigational Site
    Ciudad de Buenos Aires, Buenos Aires C1431FWO, Argentina
  • GSK Investigational Site
    Florencio Varela, Buenos Aires 1888, Argentina
  • GSK Investigational Site
    La Plata, Buenos Aires 1900, Argentina
  • GSK Investigational Site
    Mar del Plata, Buenos Aires 7600, Argentina
  • GSK Investigational Site
    Nueve de Julio, Buenos Aires B6500BWQ, Argentina
  • GSK Investigational Site
    Rosario, Santa Fe S2000DBS, Argentina
  • GSK Investigational Site
    Rosario, Santa Fe S2000JKR, Argentina
  • GSK Investigational Site
    Berazategui, 1886, Argentina
  • GSK Investigational Site
    Buenos Aires, C1425BEN, Argentina
  • GSK Investigational Site
    Ciudad Autónoma de Buenos Aires, C1121ABE, Argentina
  • GSK Investigational Site
    Mendoza, M5500CCG, Argentina
  • GSK Investigational Site
    Rosario, S2000BRH, Argentina
  • GSK Investigational Site
    Salta, A4400ERH, Argentina
  • GSK Investigational Site
    Tucuman, 4000, Argentina
  • GSK Investigational Site
    Puente Alto - Santiago, Región Metro De Santiago 8207257, Chile
  • GSK Investigational Site
    Santiago, Región Metro De Santiago 7520349, Chile
  • GSK Investigational Site
    Santiago, 8380453, Chile
  • GSK Investigational Site
    Viña del Mar, 2520594, Chile
  • GSK Investigational Site
    Tbilisi, 0119, Georgia
  • GSK Investigational Site
    Tbilisi, 0159, Georgia
  • GSK Investigational Site
    Tbilisi, 0160, Georgia
  • GSK Investigational Site
    Tbilisi, 0186, Georgia
  • GSK Investigational Site
    Mannheim, Baden-Wuerttemberg 68163, Germany
  • GSK Investigational Site
    Rosenheim, Bayern 83026, Germany
  • GSK Investigational Site
    Baunatal-Grossenritte, Hessen 34225, Germany
  • GSK Investigational Site
    Frankfurt am Main, Hessen 60596, Germany
  • GSK Investigational Site
    Neu isenburg, Hessen 63263, Germany
  • GSK Investigational Site
    Wolfenbuettel, Niedersachsen 38302, Germany
  • GSK Investigational Site
    Bochum, Nordrhein-Westfalen 44791, Germany
  • GSK Investigational Site
    Hamm, Nordrhein-Westfalen 59063, Germany
  • GSK Investigational Site
    Kleve-Materborn, Nordrhein-Westfalen 47533, Germany
  • GSK Investigational Site
    Wesel, Nordrhein-Westfalen 46483, Germany
  • GSK Investigational Site
    Koblenz, Rheinland-Pfalz 56068, Germany
  • GSK Investigational Site
    Dresden, Sachsen 01307, Germany
  • GSK Investigational Site
    Leipzig, Sachsen 04178, Germany
  • GSK Investigational Site
    Geesthacht, Schleswig-Holstein 21502, Germany
  • GSK Investigational Site
    Neuhaus am Rennweg, Thueringen 98724, Germany
  • GSK Investigational Site
    Berlin, 10785, Germany
  • GSK Investigational Site
    Hamburg, 22415, Germany
  • GSK Investigational Site
    Chiba, 260-0001, Japan
  • GSK Investigational Site
    Chiba, 273-0035, Japan
  • GSK Investigational Site
    Fukuoka, 811-1394, Japan
  • GSK Investigational Site
    Hiroshima, 720-8520, Japan
  • GSK Investigational Site
    Hokkaido, 006-0831, Japan
  • GSK Investigational Site
    Hokkaido, 064-0821, Japan
  • GSK Investigational Site
    Hyogo, 653-0021, Japan
  • GSK Investigational Site
    Kagawa, 762-0031, Japan
  • GSK Investigational Site
    Tokyo, 154-0017, Japan
  • GSK Investigational Site
    Tokyo, 157-0066, Japan
  • GSK Investigational Site
    Tokyo, 158-0097, Japan
  • GSK Investigational Site
    Wakayama, 646-8558, Japan
  • GSK Investigational Site
    Zapopan, Jalisco 45040, Mexico
  • GSK Investigational Site
    Puebla, Pue, Puebla 72000, Mexico
  • GSK Investigational Site
    Villahermosa, Tabasco 86100, Mexico
  • GSK Investigational Site
    Mexico city, 04530, Mexico
  • GSK Investigational Site
    Lima 27, Lima Lima 27, Peru
  • GSK Investigational Site
    San Miguel, Lima Lima 32, Peru
  • GSK Investigational Site
    Santiago de Surco, Lima Lima 33, Peru
  • GSK Investigational Site
    Lima, Lima 1, Peru
  • GSK Investigational Site
    Lima, Lima 27, Peru
  • GSK Investigational Site
    Cebu City, 6000, Philippines
  • GSK Investigational Site
    Manila, 1000, Philippines
  • GSK Investigational Site
    Quezon City, 1100, Philippines
  • GSK Investigational Site
    Quezon City, 1113, Philippines
  • GSK Investigational Site
    Bienkowka, 34-212, Poland
  • GSK Investigational Site
    Bydgoszcz, 85-096, Poland

Showing the first 100 of 121 sites across 14 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Oliver AJ, Covar RA, Goldfrad CH, Klein RM, Pedersen SE, Sorkness CA, Tomkins SA, Villaran C, Grigg J. Randomised trial of once-daily vilanterol in children with asthma on inhaled corticosteroid therapy. Respir Res. 2016 Apr 5;17:37. doi: 10.1186/s12931-016-0353-4. PubMed 27044326 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2012, a primary completion of Apr 2014 and a completion of Apr 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2015, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2012
First posted
Apr 10, 2012
Start
Apr 2012
Primary completionActual
Apr 2014
CompletionActual
Apr 2014
Results first posted
Apr 3, 2015
Last update
Jan 9, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01573767
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Apr 10, 2012
Start date
Apr 2012
Primary completion
Apr 2014
Completion
Apr 2014
Results posted
Apr 3, 2015
Last update
Jan 9, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vilanterol

Start the discussion